Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MNCs Consider Different Prices For Different Indian Drug Buyers

This article was originally published in PharmAsia News

Executive Summary

Multinational drug makers are considering a split of their drug pricing decisions in India, charging differently for the government, hospitals and patient-access programs. The differentiation is planned primarily for AIDS and cancer drugs as a way to gain back a greater share of the Indian market from generics makers. MNCs generally have been charging about as much for their drugs in India as in the rest of the world, but many have realized India has proved to be a smaller market than anticipated. A consultant said the firms realize they have to arrange their prices strategically if they are to compete. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts